ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the Pharmacokinetics/Pharmacodynamics (PK/PD), safety,
and effectiveness of multiple subcutaneous doses of Beloranib (ZGN-440).